Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2017 · 10-Q
Revenue$148.00K$148.00K−6.9% vs Q3 2016 Net Income-$23.27M-$23.27MN/M vs Q3 2016 EPS Diluted-$0.08-$0.08N/M vs Q3 2016 Operating Income-$14,133,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-9549.3%+6498.5 pt vs Q3 2016
Net margin-15723.6%+2658.1 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 20, 2017 · 51 d after period end